TipRanks
Sagimet Biosciences, Inc. Class A (SGMT)
NASDAQ:SGMT
US Market
SGMT
Sagimet Biosciences, Inc. Class A
RESEARCH TOOLSreports
Want to see SGMT full AI Analyst Report?

Sagimet Biosciences, Inc. Class A (SGMT) Stock News & Sentiment

1,734 Followers
Sagimet Biosciences Announces Major Equity Financing Agreement
Premium
Company Announcements
Sagimet Biosciences Announces Major Equity Financing Agreement
6d ago
8K
SGMT
Sagimet Reports Strong Phase 3 Acne Trial Results
Premium
Company Announcements
Sagimet Reports Strong Phase 3 Acne Trial Results
7d ago
8K
SGMT
Editas, Sagimet, Dropbox, Arcturus, Quanta Trending With Analysts
Premium
Weekend Updates
Editas, Sagimet, Dropbox, Arcturus, Quanta Trending With Analysts
11d ago
DBX
PWR
Sagimet Reiterated as Buy on De-Risked Acne Program and Clearer Regulatory Path; $29 Price Target Maintained
Premium
Ratings
Sagimet Reiterated as Buy on De-Risked Acne Program and Clearer Regulatory Path; $29 Price Target Maintained
1M ago
SGMT
Sagimet Wins FDA Clearance for Phase 3 Acne Trial
Premium
Company Announcements
Sagimet Wins FDA Clearance for Phase 3 Acne Trial
2M ago
8K
SGMT
Edward Nash Initiates Buy on Sagimet, Citing De-Risked Late-Stage Acne Program and Significant U.S. Market Opportunity
Premium
Ratings
Edward Nash Initiates Buy on Sagimet, Citing De-Risked Late-Stage Acne Program and Significant U.S. Market Opportunity
2M ago
SGMT
Sagimet Highlights Q2 Results and Dermatology Focus Shift
Premium
Company Announcements
Sagimet Highlights Q2 Results and Dermatology Focus Shift
2M ago
8K
SGMT
More SGMT News >

SGMT News on the Web

Sagimet Biosciences reports results from Phase 3 ASC40-304 OLE clinical trial
TipRanks News
Bullish
Sagimet Biosciences prices 8.75M shares at $10.00 in underwritten offering
TipRanks News
Neutral
Sagimet Reports Strong Phase 3 Acne Trial Results
TipRanks News
Bullish
Wall Street Analysts Are Bullish on Top Healthcare Picks
TipRanks News
Bullish
Sagimet Biosciences (SGMT): Phase 3 Trial, FDA Path and Cash Runway Set Up Key Catalysts
Insider Monkey
Neutral
Editas, Sagimet, Dropbox, Arcturus, Quanta Trending With Analysts
TipRanks News
Bearish
Goldman Sachs Resumes Coverage with a Sell Rating on Sagimet Biosciences, Inc. Class A (SGMT)
TipRanks News
Neutral
Sagimet Reiterated as Buy on De-Risked Acne Program and Clearer Regulatory Path; $29 Price Target Maintained
TipRanks News
Bullish

News Score - Last 7 Days

Positive
SGMT
Sector Average
Media Buzz
This Week12 articles
Weekly Average5 articles
News Sentiment
This Week78%
Sector Average91%
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is SGMT’s Media Buzz Sentiment?
12 articles about SGMT were published this week. In an average week, 5 articles are published.
    What is SGMT’s weekly average amount of articles?
    In an average week, 5 articles about SGMT are published.
      What is SGMT’s News Sentiment?
      78% of articles about SGMT were positive this week, compared to its sector average of 91%.
        Healthcare Stocks that are Trending in the News
        REGNRegeneron
        QTTBQ32 Bio
        NVSNovartis
        RHHVFRoche Holding AG
        KRROKorro Bio
        Showing the stocks with the most bullish news sentiment over the past week